## AMENDMENTS TO THE CLAIMS

**1. (Currently amended)** A method of examining schizophrenia in a subject, which comprises

(i) measuring concentrations~~(s)~~ of (a) D-serine, and (b) D-serine and L-serine in a biological sample of the subject,

(ii) measuring concentrations of (a) D-serine, and (b) D-serine and L-serine in a biological sample of a healthy individual or a group of healthy individuals, and calculating an average of the ratios of concentrations of (a) D-serine to (b) D-serine and L-serine, and

(iii) determining ~~wherein an index is a~~ whether the ratio of concentrations of (a)~~the~~ D-serine ~~concentration to the total serine concentration in the biological sample~~ to (b) D-serine and L-serine is lower in the subject than the average calculated in (ii).

**2-7. (Cancelled)**

**8. (Currently amended)** ~~The examination method of claim 1, wherein the index~~A method of examining schizophrenia in a subject, which comprises

(i) measuring concentrations of (a) D-serine, and (b) D-serine and L-serine in a biological sample of the subject,

(ii) measuring concentrations of (a) D-serine, and (b) D-serine and L-serine in a biological sample of a healthy individual or a group of healthy individuals, and calculating an average and a standard deviation of the ratios of concentrations of (a) D-serine to (b) D-serine and L-serine, and

(iii) determining whether the ratio of concentrations of (a) D-serine to (b) D-serine and L-serine is lower in the subject than the~~an~~ average-standard deviation calculated in (ii)~~of said ratio in a healthy individual or a group of healthy individuals~~.

**9. (Currently amended)** ~~The examination method of claim 1, wherein the index~~A method
of examining schizophrenia in a subject, which comprises

(i) measuring concentrations of (a) D-serine, and (b) D-serine and L-serine in a biological sample
of the subject,

(ii) measuring concentrations of (a) D-serine, and (b) D-serine and L-serine in a biological
sample of a healthy individual or a group of healthy individuals, and calculating an average
and a standard deviation of the ratios of concentrations of (a) D-serine to (b) D-serine and L-
serine, and

(iii) determining whether the ratio of concentrations of (a) D-serine to (b) D-serine and L-serine
is lower in the subject than the~~an~~ average+standard deviation calculated in (ii)~~of said ratio in~~
~~an individual with schizophrenia or a group of individuals with schizophrenia~~.


**10. (Cancelled)**


**11. (Currently amended)**    The examination method of any one of claims~~claim~~ 1, 8 and 9,
which uses an amino acid labeling reagent.


**12. (Previously presented)**    The examination method of claim 11, further comprising steps of
contacting an amino acid labeling reagent with the biological sample to label serine in the
sample, and separating or quantifying the labeled D-serine and the labeled L-serine.


**13. (Original)** The examination method of claim 12, further comprising a step of separating and
quantifying the labeled serine before the step of separating or quantifying the labeled D-serine
and the labeled L-serine.


**14-15. (Cancelled)**

**16. (Original)** The examination method of claim 13, wherein the labeled serine is separated or quantified using chromatography.

**17. (Cancelled)**

**18. (Previously presented)** The examination method of claim 16, wherein the chromatography is high performance liquid chromatography.

**19. (Previously presented)** The examination method of claim 12, wherein the labeled D-serine and the labeled L-serine are separated or quantified using a column or capillary.

**20. (Previously presented)** The examination method of claim 19, wherein the column or capillary is a column or capillary for optical resolution.

**21. (Previously presented)** The examination method of claim 11, wherein the amino acid labeling reagent is an amino acid fluorescence-labeling reagent.

**22. (Original)** The examination method of claim 21, wherein the amino acid fluorescence-labeling reagent is 4-fluoro-7-nitro-2,1,3-benzoxadiazole.

**23-28. (Cancelled)**